Last updated on September 2016

Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma


Brief description of study

This international multi-center, randomized, controlled, open-label study will investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of BCD-020 (NN: rituximab, CJSC Biocad) versus MabThera (INN: rituximab, F. Hoffmann La Roche, Ltd.) both administered as a monotherapy of patients with indolent non-Hodgkin's lymphoma. Patients will be randomized to receive 375 mg/m² BCD-020 as intravenous infusion once a week for 4 weeks or MabThera at the same regimen.

Clinical Study Identifier: NCT01701232

Find a site near you

Start Over

City Hospital N8

Barnaul, Russian Federation
  Connect »

Clinical Oncology Dispensary N1

Krasnodar, Russian Federation
  Connect »

Pyatigorsk Oncology Center

Pyatigorsk, Russian Federation
  Connect »

Oncology Dispensary 2

Sochi, Russian Federation
  Connect »

N.N.Petrov Oncology Research Center

St.Petersburg, Russian Federation
  Connect »

Tula Regional Hospital

Tula, Russian Federation
  Connect »

Medi-Clinic Vereeniging

Vereeniging, South Africa
  Connect »